Revenue from Contracts with Customers (Tables)

9 Months Ended

Sep. 30, 2018

We recorded the following cumulative effect as of January 1, 2018, itemized here (in thousands) and further described below:



Collaboration and license agreement revenues	$	10,281
Royalty revenues	22,230
Cost of royalty revenues	(5,955		)
Accumulated deficit – (debit) credit	$	26,556

Collaboration and license agreement revenues by collaborator are summarized as follows (in thousands):



	Three months ended September 30, 2018		Nine months ended September 30, 2018
Takeda	$	18,805	$	41,122
AbbVie	300		13,000
Genmab	—		7,000
GSK	—		6,000
Other	681		9,402
Collaboration and license agreement revenues	$	19,786	$	76,524

Impacts to September 30, 2018 condensed consolidated financial statements (in thousands)



	As reported			Adjustments			Balances without the adoption of Topic 606
Condensed Consolidated Balance Sheet data:
Accounts receivable, net	$	152,520		$	(16,730	)	$	135,790
Prepaid expenses and other current assets	26,180			(990		)	25,190
Current portion of deferred revenue	36,495			(99		)	36,396
Deferred revenue, less current portion	6,004			(16		)	5,988
Accumulated deficit	(1,204,783		)	(17,605		)	(1,222,388		)
Condensed Consolidated Statements of Comprehensive Loss data:
Three months ended September 30, 2018
Collaboration and license agreement revenues	$	19,786		$	7,448		$	27,234
Royalty revenues	22,662			(1,747		)	20,915
Total revenues	169,424			5,701			175,125
Cost of royalty revenues	5,320			826			6,146
Net loss	(67,446		)	4,875			(62,571		)
Nine months ended September 30, 2018
Collaboration and license agreement revenues	$	76,524		$	9,407		$	85,931
Royalty revenues	58,887			179			59,066
Total revenues	480,187			9,586			489,773
Cost of royalty revenues	16,845			634			17,479
Net loss	(102,888		)	8,952			(93,936		)